Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Martin Dossenbach"'
Publikováno v:
Acta Dermato-Venereologica, Vol 99, Iss 11, Pp 971-977 (2019)
Treatment goals defined by the absolute Psoriasis Area and Severity Index (PASI) scores offer certain advantages in the clinical setting. In order to investigate potential treatment targets, this study evaluated absolute PASI outcomes relative to oth
Externí odkaz:
https://doaj.org/article/a1b77587a01346cd87a844f421c5cb4c
Autor:
Gil Yosipovitch, Adam Reich, Martin Steinhoff, Anke Beselin, Toby Kent, Martin Dossenbach, Lovisa Berggren, Carsten Henneges, Thomas Luger
Publikováno v:
Dermatology and Therapy, Vol 8, Iss 4, Pp 621-637 (2018)
Abstract Introduction We evaluated baseline itch and its impact on the efficacy of ixekizumab (IXE) in clearing psoriasis and improving quality-of-life measures, and we explored the relationship between itch and psoriatic skin improvement. Methods Da
Externí odkaz:
https://doaj.org/article/83e9bed268854a089f2b86717c058754
Autor:
S Hartz, Kristian Reich, Ulrich Mrowietz, Craig L. Leonardi, Martin Dossenbach, Helmut Petto, Richard B. Warren, Daniel Saure
Publikováno v:
Journal of the European Academy of Dermatology and Venereology
Background In practice, the goal of treatment for patients with psoriasis is to achieve almost clear or clear skin and maintain disease control, regardless of baseline disease severity. However, identifying absolute Psoriasis Area and Severity Index
Autor:
Carsten Henneges, E. Schneider, Diamant Thaçi, Alexander Schacht, A. Leutz, Andreas Pinter, Kristian Reich, Matthias Augustin, Martin Dossenbach, Ulrich Mrowietz
Publikováno v:
The British Journal of Dermatology
Summary Background Interleukin‐17 antagonists have received a first‐line label for moderate‐to‐severe plaque psoriasis. Objectives We conducted the first head‐to‐head trial between the two most commonly used first‐line therapies in Germ
Publikováno v:
Acta Dermato-Venereologica, Vol 99, Iss 11, Pp 971-977 (2019)
Puig, L, Dossenbach, M, Berggren, L, Ljungberg, A & Zachariae, C 2019, ' Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis : An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes ', Acta Dermato-Venereologica, vol. 99, no. 11, pp. 971-977 . https://doi.org/10.2340/00015555-3245
ACTA DERMATO-VENEREOLOGICA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Puig, L, Dossenbach, M, Berggren, L, Ljungberg, A & Zachariae, C 2019, ' Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis : An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes ', Acta Dermato-Venereologica, vol. 99, no. 11, pp. 971-977 . https://doi.org/10.2340/00015555-3245
ACTA DERMATO-VENEREOLOGICA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Treatment goals defined by the absolute Psoriasis Area and Severity Index (PASI) scores offer certain advantages in the clinical setting. In order to investigate potential treatment targets, this study evaluated absolute PASI outcomes relative to oth
Autor:
Baojin Zhu, Martin Dossenbach, Mark Lomaga, Russel Burge, Andrew Blauvelt, David Shrom, Andreas Pinter, Wei Shen
Publikováno v:
Journal of Dermatological Treatment. 31:141-146
Background: Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin-17A, has shown superiority to ustekinumab (UST) and etanercept in skin clearance from randomiz...
Autor:
Diamant Thaçi, Stefan Wilhelm, Alice B. Gottlieb, Yuval Ramot, Martin Dossenbach, Saxon D Smith, Christopher Schuster, Daniel Saure
Publikováno v:
The Journal of dermatological treatment. 33(1)
It is challenging to select the most appropriate biologic treatment for patients with moderate-to-severe plaque psoriasis. To compare speed of onset and level of skin improvement between the interleukin (IL)-17A antagonist ixekizumab and the IL-23 p1
Autor:
Martin Dossenbach, E. Schneider, Carsten Henneges, Diamant Thaçi, Andreas Pinter, Matthias Augustin, Ulrich Mrowietz, Kristian Reich, Alexander Schacht, A. Leutz
Publikováno v:
British Journal of Dermatology. 182
Autor:
Thomas A. Luger, Anke Beselin, Adam Reich, Carsten Henneges, Lovisa Berggren, Gil Yosipovitch, Toby C. Kent, Martin Dossenbach, Martin Steinhoff
Publikováno v:
Dermatology and Therapy, Vol 8, Iss 4, Pp 621-637 (2018)
Dermatology and Therapy
Dermatology and Therapy
Introduction We evaluated baseline itch and its impact on the efficacy of ixekizumab (IXE) in clearing psoriasis and improving quality-of-life measures, and we explored the relationship between itch and psoriatic skin improvement. Methods Data were a
Autor:
Carle Paul, Lluís Puig, Martin Dossenbach, Kristin Hollister, Peter C.M. van de Kerkhof, Christopher E.M. Griffiths, Kristian Reich, Carsten Henneges, Yves Dutronc
Publikováno v:
Journal of the American Academy of Dermatology, 80, 70
Paul, C, Griffiths, C E M, van de Kerkhof, P C M, Puig, L, Dutronc, Y, Henneges, C, Dossenbach, M, Hollister, K & Reich, K 2018, ' Ixekizumab provides superior efficacy compared to ustekinumab over 52-weeks of treatment : results from IXORA-S, a phase 3 study ', Journal of the American Academy of Dermatology . https://doi.org/10.1016/j.jaad.2018.06.039
Journal of the American Academy of Dermatology, 80, 1, pp. 70
Paul, C, Griffiths, C E M, van de Kerkhof, P C M, Puig, L, Dutronc, Y, Henneges, C, Dossenbach, M, Hollister, K & Reich, K 2018, ' Ixekizumab provides superior efficacy compared to ustekinumab over 52-weeks of treatment : results from IXORA-S, a phase 3 study ', Journal of the American Academy of Dermatology . https://doi.org/10.1016/j.jaad.2018.06.039
Journal of the American Academy of Dermatology, 80, 1, pp. 70
Biologics targeting interleukin 17A (IL-17A) allow for rapid clearance of psoriatic plaques, with a clinically favorable safety profile.To compare the safety and efficacy of ixekizumab, an IL-17A antagonist, with the safety and efficacy of the IL-12/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa14df8603e4178145f95e2a61554bd2
http://hdl.handle.net/2066/201063
http://hdl.handle.net/2066/201063